{"DataElement":{"publicId":"2958252","version":"1","preferredName":"Corticosteroid Preparative Regimen Administered Type","preferredDefinition":"A description of corticosteroids administered as part of the preparative regimen.","longName":"2958243v1.0:2958250v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2958243","version":"1","preferredName":"Corticosteroid Preparative Regimen Administered","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation)._The chemotherapy and/or radiation given to blood, marrow or cord blood transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._The act of having given something (e.g., a medication or test).","longName":"2964506v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2964506","version":"1","preferredName":"Corticosteroid Preparative Regimen","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI):The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"C2322:C61155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79D8EED5-4098-537A-E040-BB89AD430FA1","latestVersionIndicator":"Yes","beginDate":"2009-12-03","endDate":null,"createdBy":"WHITES","dateCreated":"2009-12-03","modifiedBy":"ONEDATA","dateModified":"2009-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-4312-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":"2009-12-09","createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".Updated def for prep reg, no version needed. AK 12/20/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2958250","version":"1","preferredName":"Corticosteroid Type","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation)._Type; a subdivision of a particular kind of thing.","longName":"CORT_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"8223B6A1-9823-C0E8-E040-BB89AD43538F","beginDate":"2009-11-05","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"ONEDATA","dateModified":"2010-03-19","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2839905","version":"1","preferredName":"Other","longName":"2839905","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"635B8107-2331-1337-E040-BB89AD432C60","latestVersionIndicator":"Yes","beginDate":"2009-02-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-438F-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-4399-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Methylprednisolone","valueDescription":"Methylprednisolone","ValueMeaning":{"publicId":"2578269","version":"1","preferredName":"Methylprednisolone","longName":"2578269","preferredDefinition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-43A3-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Beclomethasone","valueDescription":null,"ValueMeaning":{"publicId":"5678498","version":"1","preferredName":"Beclomethasone","longName":"5678498v1.00","preferredDefinition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beclomethasone Dipropionate","conceptCode":"C299","definition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7484-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F44E56-74EC-5C5A-E063-731AD00A89D3","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Budesonide","valueDescription":null,"ValueMeaning":{"publicId":"3305276","version":"1","preferredName":"Budesonide","longName":"3305276","preferredDefinition":"A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0D5C-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F44E56-74ED-5C5A-E063-731AD00A89D3","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"None","valueDescription":null,"ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F8947F-DB8E-2116-E063-731AD00A4BA8","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2964507","version":"1","preferredName":"Corticosteroid Type","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI):Type; a subdivision of a particular kind of thing.","longName":"C2322:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79D8EED5-411A-537A-E040-BB89AD430FA1","latestVersionIndicator":"Yes","beginDate":"2009-12-03","endDate":null,"createdBy":"WHITES","dateCreated":"2009-12-03","modifiedBy":"ONEDATA","dateModified":"2009-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-4372-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":".","administrativeNotes":"2023.8.2 Added PVs per ticket request CADSR0002666. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964872","version":"1","longName":"2000r1: Recipient Baseline Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"MaterialName:name","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What type of corticosteroids","type":"Preferred Question Text","description":"What type of corticosteroids were administered for the preparative regimen?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2958252","type":"BRIDG Mapping Path","description":"\"PerformedSubstanceAdministration > DefinedSubstanceAdministration > Product > MaterialName.name WHERE Product.typeCode = \"\"CorticoSteroids\"\" AND DefinedSubstanceAdministration > DefinedCompositeRelationship >  DefinedProcedure.nameCode = \"\"Perform composite preparative regimen\"\"\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-43B7-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":". Updated def for prep reg, no version needed. AK 12/20/13 Added human readable def. System generated def displayed as alt def. No version needed. AK 10/16/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}